Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine

Neuroscience Letters

Volumn 463, Issue 3, 2009, Pages 210-214

  Góngora Alfaro, José L ^a   Moo Puc, Rosa E ^b   Villanueva Toledo, Jairo R ^a   Alvarez Cervera, Fernando J ^a   Bata García, José L ^a   Heredia López, Francisco J ^a   Pineda, Juan C ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Catalepsy; Chronic caffeine; Methylxanthines; Neuroprotection; Parkinson's disease; Wistar rats

Indexed keywords

CAFFEINE; DOPAMINE RECEPTOR; DRINKING WATER; HALOPERIDOL; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CATALEPSY; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; IMMOBILIZATION; LATENT PERIOD; MALE; METABOLITE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SCORING SYSTEM;

EID: 68949206223     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.07.084     Document Type: Article

References (30)

1. Agnati L.F., Ferré S., Lluis C., Franco R., and Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev. 55 (2003) 509-550
2. Altun M., Bergman E., Edström E., Johnson H., and Ulfhake B. Behavioral impairments of the aging rat. Physiol. Behav. 92 (2007) 911-923
3. Alvarez-Cervera F.J., Villanueva-Toledo J., Moo-Puc R.E., Heredia-López F.J., Alvarez-Cervera M., Pineda J.C., and Góngora-Alfaro J.L. A novel automated rat catalepsy bar test system based on a RISC microcontroller. J. Neurosci. Meth. 146 (2005) 76-83
4. Ascherio A., Weisskopf M.G., O'Reilly E.J., McCullough M.L., Calle E.E., Rodriguez C., and Thun M.J. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am. J. Epidemiol. 160 (2004) 977-984
5. 2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21 (2001) RC143 (1-6)
6. Datta U., Noailles P.A., Rodriguez M., Kraft M., Zhang Y., and Angulo J.A. Accumulation of tyrosine hydroxylase messenger RNA molecules in the rat mesencephalon by chronic caffeine treatment. Neurosci. Lett. 220 (1996) 77-80
7. Evans A.H., Lawrence A.D., Potts J., MacGregor L., Katzenschlager R., Shaw K., Zijlmans J., and Lees A.J. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 77 (2006) 317-321
8. Feely J., Kelleher P., and Odumosu A. The effects of ageing on aminopyrine and caffeine breath tests in the rat. Fundam. Clin. Pharmacol. 1 (1987) 409-412
9. Fredholm B.B., Battig K., Holmen J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51 (1999) 83-133
10. Goicoechea C., Ormazábal M.J., Alfaro M.J., and Martín M.I. Age-related changes in nociception, behavior, and monoamine levels in rats. Gen. Pharmacol. 28 (1997) 331-336
11. J.L. Góngora-Alfaro, R.E. Moo-Puc, J. Villanueva-Toledo, F.J. Alvarez-Cervera, F.J. Heredia-López, J.L. Bata-García, J.C. Pineda-Cortés, Male rats chronically treated with caffeine display increased exploratory behavior and resistance to haloperidol-induced catalepsy, Program No. 265.2/T21 2007 Neuroscience Meeting Planner, San Diego, CA, Society for Neuroscience, 2007 (Online).
12. Guerreiro S., Toulorge D., Hirsch E., Marien M., Sokoloff P., and Michel P.P. Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol. Pharmacol. 74 (2008) 980-989
13. Hu G., Bidel S., Jousilahti P., Antikainen R., and Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Movement Disord. 22 (2007) 2242-2248
14. 2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80 (2002) 262-270
15. Joghataie M.T., Roghani M., Negahdar F., and Hashemi L. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat. Disord. 10 (2004) 465-468
16. Lau C.E., and Falk J.L. Tolerance to oral and IP caffeine: locomotor activity and pharmacokinetics. Pharmacol. Biochem. Behav. 48 (1994) 337-344
17. Lin S.Y., Hou S.J., Perng R.I., Chen S.M., and Young T.K. Effect of traditional Chinese herbal medicines on the pharmacokinetics of western drugs in Sprague-Dawley rats of different ages (II): aminophylline-huan shao tan and aminophylline-pu chung yi chi tang. Mech. Ageing Dev. 66 (1992) 93-106
18. Machado A., CanoJ J., and Santiago M. The change with age in biogenic amines and their metabolites in the striatum of the rat. Arch. Gerontol. Geriatr. 5 (1986) 333-342
19. 2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 328 (1997) 135-141
20. Moo-Puc R.E., Góngora-Alfaro J.L., Alvarez-Cervera F.J., Pineda J.C., Arankowsky-Sandoval G., and Heredia-López F. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Neuropharmacology 45 (2003) 493-503
21. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., Tung K.H., Tanner C.M., Masaki K.H., Blanchette P.L., Curb J.D., Popper J.S., and White L.R. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000) 2674-2679
22. Sääksjärvi K., Knekt P., Rissanen H., Laaksonen M.A., Reunanen A., and Männistö S. Prospective study of coffee consumption and risk of Parkinson's disease. Eur. J. Clin. Nutr. 62 (2008) 908-915
23. Sánchez H.L., Silva L.B., Portiansky E.L., Herenu C.B., Goya R.G., and Zuccolilli G.O. Dopaminergic mesencephalic systems and behavioral performance in very old rats. Neuroscience 154 (2008) 1598-1606
24. High receptors in the striatum of rats sensitized to caffeine motor effects. Synapse 62 (2008) 394-397
25. Smith C., Ma F., and Lau C.E. Dose independent pharmacokinetics of caffeine after intravenous administration under a chronic food-limited regimen. Drug Metab. Drug Interact. 15 (1999) 83-96
26. 2A receptors and zif-268 mRNAs in striatal neurons. J. Neurochem. 98 (2006) 1078-1089
27. Vasconcelos-Aguiar L.M., Nobre Jr. H.V., Macêdo D.S., Oliveira A.A., Freitas R.M., Vasconcelos S.M., Cunha G.M.A., Sousa F.C.F., and Viana G.S.B. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol. Biochem. Behav. 84 (2006) 415-419
28. Xu K., Xu Y., Brown-Jermyn D., Chen J.F., Ascherio A., Dluzen D.E., and Schwarzschild M.A. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 26 (2006) 535-541
29. Xu K., Xu Y.H., Chen J.F., and Schwarzschild M.A. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322 (2002) 13-16
30. 2A receptor knockout mice with microarray profiling. Physiol. Genomics 37 (2009) 199-210